GNCA vs. HTGMQ, KLDO, UTRS, VIVE, ONCSQ, AHPI, VRAYQ, NOVNQ, HGEN, and ALVO
Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include HTG Molecular Diagnostics (HTGMQ), Kaleido Biosciences (KLDO), Minerva Surgical (UTRS), Viveve Medical (VIVE), OncoSec Medical (ONCSQ), Allied Healthcare Products (AHPI), ViewRay (VRAYQ), NVN Liquidation (NOVNQ), Humanigen (HGEN), and Alvotech (ALVO). These companies are all part of the "medical" sector.
HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
Genocea Biosciences received 388 more outperform votes than HTG Molecular Diagnostics when rated by MarketBeat users.
In the previous week, Genocea Biosciences had 2 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 2 mentions for Genocea Biosciences and 0 mentions for HTG Molecular Diagnostics. Genocea Biosciences' average media sentiment score of 0.00 equaled HTG Molecular Diagnostics'average media sentiment score.
HTG Molecular Diagnostics has higher revenue and earnings than Genocea Biosciences.
Genocea Biosciences' return on equity of 0.00% beat HTG Molecular Diagnostics' return on equity.
0.6% of Genocea Biosciences shares are held by institutional investors. 2.6% of HTG Molecular Diagnostics shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
HTG Molecular Diagnostics has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
Summary
HTG Molecular Diagnostics beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.
Get Genocea Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genocea Biosciences Competitors List
Related Companies and Tools
